Strs Ohio Takes $994,000 Position in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Strs Ohio has established a new position in Catalyst Pharmaceuticals, Inc. by acquiring 41,000 shares valued at approximately $994,000 in the first quarter.
• Institutional investors and hedge funds now collectively own 79.22% of Catalyst Pharmaceuticals' stock, indicating strong institutional interest in the biopharmaceutical company.
• The stock has a 52-week range of $19.15 to $26.58 and currently has an average rating of "Buy" from analysts, with a consensus price target of $33.20.

Strs Ohio acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 41,000 shares of the biopharmaceutical company's stock, valued at approximately $994,000.

Several other large investors also recently made changes to their positions in the business. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals in the 4th quarter worth about $29,000. Sound Income Strategies LLC bought a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $64,000. GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 57.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock worth $133,000 after buying an additional 2,002 shares during the last quarter. Finally, US Bancorp DE grew its stake in shares of Catalyst Pharmaceuticals by 17.8% in the first quarter. US Bancorp DE now owns 7,328 shares of the biopharmaceutical company's stock worth $178,000 after purchasing an additional 1,105 shares during the last quarter. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Trading Down 3.0%

CPRX traded down $0.62 during midday trading on Friday, hitting $19.78. 3,557,554 shares of the company were exchanged, compared to its average volume of 1,529,074. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.15 and a 1-year high of $26.58. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of 11.99, a price-to-earnings-growth ratio of 0.80 and a beta of 0.85. The company's 50 day simple moving average is $20.56 and its 200 day simple moving average is $22.30.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, CEO Richard J. Daly sold 22,970 shares of the stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total transaction of $473,641.40. Following the completion of the sale, the chief executive officer owned 226,794 shares in the company, valued at approximately $4,676,492.28. This represents a 9.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian Elsbernd sold 30,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $20.30, for a total transaction of $609,000.00. Following the completion of the transaction, the insider directly owned 271,039 shares in the company, valued at approximately $5,502,091.70. This represents a 9.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 243,970 shares of company stock valued at $4,927,241 in the last quarter. Insiders own 10.40% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Sunday. Finally, Zacks Research lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $33.20.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.